Interview: How 4.5MM Late-Stage Neuro Patients Drive Opportunity For MRI Interventions

Print E-mail
By Staff and Wire Reports   
Tuesday, 18 September 2012 13:32

icon_ceoexclusive2.2 Million late-stage neuro-patients are "stranded", according to MRI Interventions (OTCBB:MRIC) CEO Kimble Jenkins, who explains that neurosurgeons have been performing minimally invasive brain surgeries using technologies dating back at least 60 years.

"The surgeons essentially perform these procedures blind," says Jenkins, whose company has developed a next-generation imaging platform that allows neurosurgeons to see inside a patient's brain in real-time during procedures. 

The company hopes to revolutionize neurosurgery using MRI imaging similar to how the endoscope revolutionized orthopedic surgery or how fluoroscopy changed the dynamics of cardiovascular procedures. 

Worldwide, the company estimates there are 4.5 Million late-stage neuro patients that could benefit from a platform that enables targeted deep-brain stimulation, focal ablation, and direct drug delivery therapies. Communities' desire to take care of patients with treatment-resistant Parkinson's, Alzheimer's, Brain Tumors, OCD, and other neurologic diseases drives a very large opportunity for MRI Interventions, likening the company to names such as MAKO Surgical (NASDAQ:MAKO) or Intuitive Surgical (NASDAQ:ISRG), which drive value via superior surgical platforms in other areas. 

Companies such as CellDex Therapeutics (NASDAQ:CLDX), ImmunoCellular Therapeutics (AMEX:IMUC) or Agenus (NASDAQ:AGEN), who are developing experimental therapies targeting brain tumors, can utilize MRI Interventions’ technology as a direct delivery platform for their drugs. In facilitating the delivery of these, and other, experimental therapies, MRI Interventions creates risk-mitigated exposure to the future of treating neurologic diseases. As an intermediary in the delivery of therapeutics, MRI Interventions benefits from the recurring use of its technology, which drives revenues and cash-flows. 

In an exclusive video interview, MRI Interventions Chief Executive Officer, Kimble Jenkins, discusses the company's outlook and growth prospects, utilization of ClearPoint - the company's MRI-guided visualization platform - and research & development efforts, particularly a next-generation visualization platform that will guide surgeons in catheter-based cardiac EP procedures.






BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BioMedReports XOMA Initiates Trial of Gevokizumab; Sarepta Reports Favorable Safety Results of AVI-7100: Below is a look at ... http://t.co/S88hJTdtan
14hreplyretweetfavorite
BioMedReports Study says hepatitis C will be a rare disease by about 2036 http://t.co/SfrOoDv2CD
14hreplyretweetfavorite
BioMedReports Healthcare Review: Catalyst Pharmaceuticals, Can-Fite BioPharma, Acasti Pharmaceuticals, Northwest Biotherapeu... http://t.co/7OWLgqgTqM
17hreplyretweetfavorite

Newsletter